Published: December 2025 | Last updated: May 2026
The CDC's annual STI surveillance report is the document most reporters reach for when they describe what is happening with sexual health in the United States. It catalogues confirmed cases of chlamydia, gonorrhea, syphilis, congenital syphilis, and a handful of other infections, broken out by state, age group, race, and reporting year. The picture it paints shapes prevention budgets, clinical guidelines, and how the story gets told.
Here is the part that rarely makes the headline. That picture only includes what flows through clinics, hospital labs, and state surveillance systems. Anyone who tests at home with a rapid kit, treats privately through a telehealth provider, or buys an over-the-counter remedy and never sees a clinician is missing from the count. As at-home testing volume rises, the gap between the federal scorecard and the lived reality of sexual health in 2026 keeps widening.
Why Some STIs Never Show Up in the Data
National STI surveillance has always depended on a chain of hand-offs. A clinician orders a test, a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (a federally regulated testing facility) processes it, the lab reports the positive result to the state health department, and the state forwards aggregated data to the federal level. That chain is the basis of every figure in the CDC's annual STI Statistics. Break any link in it and the case never reaches the count.
Several increasingly common testing paths break the chain by design. A self-read rapid cassette in your bathroom never touches a state lab. A mail-in kit processed by a CLIA-certified lab may or may not be a reportable result depending on the lab's relationship with the state. A telehealth visit that ends with antibiotics shipped to your door may have no diagnosis code that ever lands in a surveillance system. Each of these is a legitimate way to handle an exposure, and each is invisible to the federal data.
That invisibility is not a small rounding error. STIs that are heavily diagnosed outside clinics, especially genital herpes and HPV, have always been undercounted in surveillance. Asymptomatic chlamydia in adults under 30 is widely tested at home today, often via combination kits sold direct to consumers.
Does my at-home STD test get reported to the CDC?
Almost never. The CDC counts cases that move through state surveillance: clinic visits, results from CLIA-certified labs with reporting agreements, and clinician-initiated reports. Rapid lateral-flow tests you read at home, anonymous telehealth consults, and over-the-counter treatments without testing do not enter the data unless you take the result to a provider. Your test is still valid, it just is not counted.
The Shame Loop: Why Many Test Without Telling Anyone
The gap is not only about where the test happens. It is also about what happens after. A meaningful share of people who test positive never follow up with a provider, never tell a partner formally, and never enter the loop where a case becomes a reported case.
The reasons are not mysterious. Online support forums fill with messages from people sitting with a faint positive line and no idea who they can safely tell. In many states, even when a lab runs the test, if no prescription is filled and no clinic visit follows, the diagnosis may never be documented in a way that reaches surveillance. The silence is not only personal. It is structural. And it tends to weigh hardest on the people who already have the most reason to be cautious about the medical system: young LGBTQ+ readers, undocumented patients, people who have been dismissed or shamed at urgent care before, and people of color who navigate a documented history of medical mistrust.
What Gets Counted, and What Doesn't
The mechanics of STI surveillance vary by infection and state, but the broad pattern is consistent. Clinic-based testing and physician-ordered lab work feed the data. Self-paid, self-read, and unreported tests usually do not. The table below summarizes the most common testing routes and where each one lands in the count.
| Test Type | Reported to CDC? | Notes |
|---|---|---|
| Public health clinic testing | Yes | Standard pathway through state surveillance systems |
| Private physician visit with lab work | Yes | CLIA-certified lab reports the positive result; clinician may follow up |
| Mail-in STD kit processed by a CLIA lab | Sometimes | Depends on the lab's state reporting agreements and the specific infection |
| At-home rapid lateral-flow cassette | No | User reads the result; no clinician or lab record exists to report |
| Telehealth treatment without testing | No | Empirical antibiotics with no diagnosis code rarely generates a reportable case |
| Over-the-counter remedies (no test) | No | Common for vaginal symptoms; no formal diagnosis ever happens |
Inside the Reporting Gap: How a Real Case Stays Invisible
Sexual-health writers hear a version of the same story over and over. A reader in a small town, far from the nearest sexual-health clinic, has an unprotected encounter. A week or two later they feel off, a sore throat, a low-grade fever, something they cannot quite place. They order an at-home kit online because it arrives in a discreet box and they can do it without booking time off work or driving to a clinic where they might run into someone they know.
The result is positive. They sign up for a telehealth consult, get a prescription, finish the antibiotics, and never speak to their primary care doctor about it. They did not want it in their chart. They did not want to file insurance. They paid out of pocket and moved on with their life. Clinically, the infection is resolved. Statistically, it never happened.
Patterns like this are not rare. They are the predictable consequence of giving people convenient, private testing options without an easy way to feed those results into public health data.
The Rise of At-Home Testing and What It Changes
Accessible testing is unambiguously a good thing. Rapid lateral-flow cassettes, mail-in collection kits, and same-day telehealth options have helped people detect infections sooner, start treatment faster, and avoid clinics that previously felt unwelcoming or impossible to reach. None of that should be unwound. Privacy and access reduce real barriers to care.
What has changed is the center of gravity of testing. Direct-to-consumer kits and pharmacy-shelf rapid tests for HIV, syphilis, and combination panels are now part of how a meaningful share of people approach sexual health, especially readers under 35 and those in regions where the nearest sexual-health clinic is hours away. Surveillance systems built around clinic visits do not see most of this activity.
The paradox is real. The more people test, the less the official numbers reflect what is being found in homes, bedrooms, and discreet telehealth consults across the country.
We sell at-home rapid STI kits, and the panel below covers several of the infections discussed in this article. Read on for context on how rapid kits fit alongside clinic and lab-based testing.
Why the Skew Matters, and Who It Costs
Funding for STI services often follows reported case counts. If a city's syphilis numbers do not show a spike, the city probably will not get extra outreach dollars. If queer teens in a rural state test positive via telehealth and never reach a clinic, their need does not show up on the map planners use to decide where to place services.
There is a knock-on effect for public perception too. If reported chlamydia diagnoses drop in a state where home testing is rising, the headline might read like progress. The reality could be flat or worse, just shifted out of the data stream. That is a hard problem to communicate, and it leaves a lot of room for misreading the trend.
The equity dimension is sharper. Black Americans have consistently accounted for a disproportionate share of reported STIs in the CDC's surveillance year after year, despite making up a much smaller share of the population. Providers and advocates who work in affected communities have long argued that even that gap understates reality, because medical mistrust, insurance gaps, and care-access barriers all push real cases further from the reporting system. If the map is broken, prevention money lands in the wrong places.
Many sexually transmitted infections go undiagnosed and unreported, and the reported case count reflects only a fraction of the true burden of disease.
Making Your At-Home Test Count, Even When It's Private
If you have already tested at home, or you are planning to, you are not doing anything wrong. You are doing something proactive. The question is what to do next so the result leads to good care for you and the people you have been close to.
If your positive result came from a mail-in kit processed by a CLIA-certified lab, ask the service whether the result gets reported in your state. Many do, some do not, and it is a reasonable thing to know. If reporting matters to you and the service does not handle it, a brief telehealth or in-person follow-up with a provider creates a record that flows into the public-health system the normal way.
If your result came from a rapid lateral-flow cassette you read at home, the result by itself is not going to be in any database. Bringing it to a provider for confirmation lets you do two things: get a confirmatory test using the lab methods (NAAT and PCR) that surveillance is built around, and start treatment under medical supervision. Lateral-flow tests are useful screens, the labs use higher-sensitivity molecular methods. The two are complementary, not equivalent. The WHO's STI fact sheet describes the broader testing-and-treatment chain in plain language if you want more context.
Partner notification is the other piece. You do not have to do it in person or by name. Tools like TellYourPartner.org and most state health departments offer anonymous notification options that give someone else the information they need to test and treat in time.
The Case for Better, Privacy-Respecting Surveillance
Nobody serious is arguing that people should give up the privacy and convenience of testing at home. Privacy is part of why testing is happening at all for a lot of readers, and forcing those tests back into clinic settings would push case counts down by suppressing testing, not by reducing disease.
What public-health researchers have been pushing for instead is the missing layer between the test and the data: ways to capture results from people testing outside clinics, without forcing them back into the clinic chain. The technology to do this in a privacy-respecting way is not speculative; what is missing is the policy and funding to standardize it. A surveillance system that meets people where they test, in bathrooms, bedrooms, telehealth apps, and pharmacy aisles, can keep up with where sexual health is being managed.
What an At-Home Positive Test Means for You, Right Now
The big-picture data problem is real, and it is not a problem you have to solve. What is worth keeping clear in your own head is simpler: your test result is information about your body, and it is worth acting on regardless of whether the number ever shows up in a federal report. The body, the timeline, and the decision all belong to you.
And if you have already done all of that quietly, off the books, and moved on, that is not a failure of citizenship. The reporting gap is not your obligation to close. It is a system-design problem. Your job is to take care of yourself and the people you are close to.
FAQs
- Does the CDC know about my at-home STD test result?
- Mail-in kits processed by a CLIA-certified lab with state reporting agreements sometimes enter the surveillance count, so it is worth asking the service directly. A rapid lateral-flow cassette you read at home almost never does; the result stays with you unless you bring it to a clinic or telehealth provider. Infection type also matters, since herpes and HPV are rarely reportable to state systems even when a lab runs the test, while chlamydia, gonorrhea, syphilis, and HIV usually are.
- Can I treat an STI without going to a clinic?
- Yes, and many people do. If you test positive using a reputable at-home kit, several telehealth services can prescribe and ship treatment to your door. Pick a service that connects you to a licensed clinician rather than one that only sells tests. Confirming a positive result with a lab test is still the right move when the option is available, but a careful telehealth path is a real path.
- Why do STI stats always seem low compared to what people describe online?
- Because the published numbers only include cases that move through reportable clinical and lab pathways. Tens of thousands of people test and treat outside that pathway every month. The official count understates the real picture in a structural way, not a one-year fluke. That is part of why advocates push for privacy-respecting self-report channels.
- What is a silent STI, and should I be worried?
- Silent means asymptomatic, not harmless. Chlamydia, trichomoniasis, and gonorrhea can sit in the body for weeks or months without symptoms, especially in people with vaginas. The infection can still be transmitted and can still cause complications like pelvic inflammatory disease or fertility issues if it goes untreated. Routine testing is the only reliable way to catch a silent infection in time.
- I got a faint line on my rapid test. Does that mean it is positive?
- In most rapid-test designs, yes. A faint test line is still a test line. Lateral-flow chemistry is built so that any visible line in the test region indicates a positive result, similar to a pregnancy test. Confirm the result with a provider or a lab-based test when you can, but do not dismiss it because the line is not bold.
- I treated myself after testing positive. Am I clear now?
- Probably, if you completed the full course and the regimen matched current guidance for that infection. Retesting three to four weeks after finishing treatment is the cleanest way to be sure, especially for chlamydia and gonorrhea where reinfection from an untreated partner is common. If a partner did not get treated, there is a real chance of bouncing the infection back and forth.
- How can I tell a partner without making it harder for both of us?
- Anonymous tools like TellYourPartner.org let you send a heads-up without your name attached. If you want to tell someone directly, keep it short and factual: a recent test came back positive and they should consider testing too. You are not assigning blame, you are giving them the same information you would want.
- I am nervous about testing at all. What should I know?
- Most STIs are treatable, all of them are manageable, and not knowing is usually worse than knowing. Testing is one of the few parts of sexual health you can do entirely on your own timeline, in your own space. If a clinic feels off-limits, an at-home kit is a reasonable first step. Whatever the result, you will have more options than you had ten minutes earlier.
- U.S. Centers for Disease Control and Prevention. STI Statistics overview: how national surveillance works and what it covers.
- U.S. Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance, 2024 annual report.
- World Health Organization. Sexually transmitted infections (STIs) fact sheet, including diagnosis and treatment pathways.
- U.S. Centers for Disease Control and Prevention. HIV statistics overview: National HIV Surveillance System and monitoring programs.
- U.S. Centers for Disease Control and Prevention, NCHHSTP director letter releasing the 2024 national STI data.
